Non-Small Cell Lung Cancer: Symptoms, Stages, Treatment

What Is Non-Small Cell Lung Cancer?

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. It makes up around 80 to 85 percent of all lung cancer cases. The disease starts when lung cells become uncontrolled and form a tumor. NSCLC grows more slowly than small-cell lung cancer. But it can still spread to other organs before symptoms show up.

What Are the Various Types of Non-Small Cell Lung Cancer?

NSCLC is a label, not a single disease. It groups several lung cancers whose cells do not look small under a microscope.

Three subtypes account for most cases.

• Adenocarcinoma: It is the most common type, accounting for around 40 percent of all lung cancers. It usually starts in the outer parts of the lung and is the main type seen in people who have never smoked.

• Squamous Cell Carcinoma: They make up roughly 25 to 30 percent of cases and tend to grow in the central airways. Smoking is the main driver.

• Large Cell Carcinoma: It accounts for about 10% of cases. It accounts for about 10 percent. It grows fast. It can appear anywhere in the lung.

Other subtypes include adenosquamous carcinoma, sarcomatoid carcinoma, and pulmonary carcinoid tumors.

Symptoms of Non-Small Cell Lung Cancer?

Early NSCLC often shows nothing at all. Most symptoms appear once the tumor is larger or has spread.

Many people don’t notice symptoms early.

Common signs to watch for:

• A cough that does not go away.

• Coughing up blood or rust-colored sputum.

• Shortness of breath, sometimes with wheezing.

• Chest pain that gets worse with deep breathing.

• Hoarseness lasting more than two weeks.

• Weight loss without trying.

• Fatigue, weakness, and loss of appetite.

If the cancer has spread, new symptoms can show up: bone pain, headaches, jaundice (yellowing of the skin), or swelling in the face and neck. Any cough lasting over three weeks must be investigated. Talk to a pulmonary expert online for clarity regarding your symptoms.

What Causes Non-Small Cell Lung Cancer?

Smoking is the leading cause. According to the CDC (2024), 80 to 90 percent of all lung cancer fatalities in the United States can be attributed to tobacco use. Tobacco consumption is the primary contributing factor; however, other factors also contribute.

Other risk factors include:

• Secondhand smoke at home or work.

• Radon is an odorless radioactive gas that builds up in basements and lower floors.

• Workplace exposure to asbestos, silica dust, diesel exhaust, or arsenic.

• Long-term exposure to fine particulate air pollution.

• A close family member with lung cancer.

• Past radiation therapy to the chest.

• A history of lung diseases, such as COPD or pulmonary fibrosis.

People who never smoked still get lung cancer, and adenocarcinoma is the type seen most often in that group.

How Is Non-Small Cell Lung Cancer Diagnosed?

A diagnosis typically starts with the identification of an abnormality on imaging or recurring symptoms. The physician reviews the patient’s medical history, obtains information on smoking and exposures, and performs tests.

Common diagnostic tests:

• A chest X-ray is often the first imaging done.

• Computed Tomography (CT) scan for detailed cross-sectional images.

• Positron Emission Tomography (PET) scan to look for spread.

• Magnetic Resonance Imaging (MRI) is used to check the brain for spread.

• A biopsy through a needle or bronchoscope, which confirms the diagnosis.

• Sputum cytology, which checks coughed-up mucus for cancer cells.

The lab also runs molecular tests on the tumor sample. Doctors may test the tumor for specific gene changes such as EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1, and KRAS. Results decide whether targeted drugs are an option.

What Are the Stages of Non-Small Cell Lung Cancer?

Doctors stage NSCLC using the TNM system, which looks at tumor size (T), lymph node spread (N), and metastasis (M).

Stages go from 0 to 4B.

Stage	What It Means
Stage 0	Cancer cells are confined to the airway lining. No spread.
Stage 1A	Tumor 3 cm or smaller. Confined to the lung.
Stage 1B	Tumor between 3 and 4 cm. No lymph node spread.
Stage 2A	Tumor between 4 and 5 cm. Lymph node not involved.
Stage 2B	Tumor up to 7 cm with nearby lymph node spread.
Stage 3	Cancer has reached the lymph nodes in the chest. Three substages (3A, 3B, 3C).
Stage 4A	Spread within the chest or to one site outside it.
Stage 4B	Spread to multiple distant sites or organs.

Stage at diagnosis is the strongest predictor of outcome.

How Is Non-Small Cell Lung Cancer Treated?

Treatment depends on stage, subtype, gene mutations, and the patient's overall health. Most people receive a combination. Not everyone needs all these treatments. Your doctor will choose what fits your stage and health. Such as:

1. Surgery: Surgery is the main option for early-stage NSCLC.

The four common procedures:

• Lobectomy removes the lobe of the lung holding the tumor. Most common.

• Pneumonectomy removes the entire lung, used for large or central tumors.

• Segmentectomy removes a segment of a lobe.

• Wedge resection takes out a small wedge of tissue around the tumor.

2. Radiation Therapy: Radiation kills cancer cells with high-energy beams.

Three main types are used in NSCLC:

• Stereotactic body radiation therapy (SBRT) involves administering radiation at high dosages within five sessions or fewer to early-stage small tumors.

• Stereotactic radiosurgery (SRS) treats brain metastases in one or two sessions.

• Standard fractionated radiation runs daily for up to six weeks for locally advanced disease.

3. Chemotherapy: Here, medications are administered either intravenously or orally. Chemotherapy may be used together with radiation therapy, following surgery to eliminate residual cancer cells, or as a primary therapy for metastatic cancer.

4. Targeted Therapy: These drugs work on tumors with specific gene changes. Osimertinib targets EGFR mutations. Crizotinib and Alectinib target ALK rearrangements. When the right mutation is present, targeted drugs often work better than chemotherapy and have milder side effects.

5. Immunotherapy: Immunotherapy drugs such as Pembrolizumab and Nivolumab help the immune system find and attack cancer cells. They are often used in advanced NSCLC and have changed survival for many patients in the last decade.

Treatment by Stage

NSCLC Stage	Common Treatments
Stage 0	Surgery alone, sometimes laser or photodynamic therapy.
Stage 1	Surgery, sometimes followed by chemotherapy.
Stage 2	Surgery plus chemotherapy, with radiation if surgery is not possible.
Stage 3	Chemotherapy with radiation, often followed by immunotherapy. Surgery in select cases.
Stage 4	Targeted therapy, immunotherapy, chemotherapy, or palliative care.

If you or a family member has been diagnosed, consulting with a specialist can help clarify the treatment plan and second-opinion options. Treatments have improved significantly in recent years.

What Is the Survival Rate for Non-Small Cell Lung Cancer?

Survival depends on how far the cancer has spread at diagnosis. The American Lung Association 2025 report gives these five-year relative survival rates for lung cancer overall:

• 65 percent for localized disease.

• 37 percent for regional disease (spread to nearby lymph nodes).

• 10 percent for distant disease.

NSCLC tends to do slightly better than small-cell lung cancer at the same stage. Newer drugs, particularly immunotherapy and targeted therapy, are pushing these numbers up year after year. Two patients with the same stage can still have very different outcomes.

How Can Non-Small Cell Lung Cancer Be Prevented?

The single most useful step is to stop smoking. Risk drops within a few years of quitting and continues to fall.

Other prevention steps:

• Avoid secondhand smoke at home and at work.

• Test the home for radon. Levels above 4 pCi/L need fixing.

• Use protective equipment when working around asbestos, silica, or diesel fumes.

• Eat a diet built around vegetables and fruit.

• Stay physically active.

For people aged 50 to 80 who currently smoke or have quit within the last 15 years and have a 20-pack-year history, the United States Preventive Services Task Force (USPSTF, 2021) recommends yearly low-dose CT (LDCT) screening. Screening is shown to lower lung cancer deaths by about 20 percent in this group.

Conclusion

Non-small cell lung cancer is serious, but the picture has changed. Surgery cures many early-stage cases. Targeted drugs and immunotherapy have shifted outcomes for advanced disease in ways that were not on the table a decade ago. The earlier the cancer is found, the wider the treatment options. If a cough has lingered, if breathing has changed, or if smoking history puts you in the high-risk group, do not wait. Speak with our cancer specialist online today to understand your risk and act early.

Key Takeaways

• NSCLC accounts for 80 to 85 percent of all lung cancer cases.

• The three main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

• Smoking causes most cases, but radon, asbestos, and air pollution also raise the risk.

• Stage at diagnosis is the strongest factor in survival outcomes.

• Treatment now includes surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.